HPV Vaccination and Screening with High-Performance Test: Brazilian Evidence

Brazil has a critical issue on women's health to solve: one woman dies every 90 minutes due to cervical cancer with a mean age of 45 years.[1] Considered eradicable cancer, there are two established strategies to control it: vaccination against HPV and periodic screening for detection of precancerous lesions. The Brazilian public health system offers both, free of charge, although this is not enough.

Publication History

Article published online:
21 December 2021

• References

• 1 Ministério da Saúde. Instituto Nacional de Câncer Jose Alencar Gomes da Silva. [Estimate 2020: cancer incidence in Brazil] [Internet]. Rio de Janeiro: INCA; 2019 [cited 2021 Jun 22]. Available from: https://www.inca.gov.br/sites/ufu.sti.inca.local/files//media/document//estimativa-2020-incidencia-de-cancer-no-brasil.pdf. Portuguese
• 2 Garland SM, Cornall AM, Brotherton JML, Wark JD, Malloy MJ, Tabrizi SN. VACCINE study group. Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women, following eight years of a national vaccination program. Vaccine 2018; 36 (23) 3221-3230 DOI: 10.1016/j.vaccine.2018.04.080.
• 3 Falcaro M, Castañon A, Ndlela B. et al. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. Lancet 2021;398(10316):2084–2092 10.1016/S0140-6736(21)02178-4 [ahead of print]
• 4 Drolet M, Bénard É, Pérez N, Brisson M. HPV Vaccination Impact Study Group. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet 2019; 394 (10197): 497-509 DOI: 10.1016/S0140-6736(19)30298-3.
• 5 Lei J, Ploner A, Elfström KM. et al. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med 2020; 383 (14) 1340-1348 DOI: 10.1056/NEJMoa1917338.
• 6 Ministério da Saúde. SI-PNI - Sistema de Informação do Programa Nacional de Imunizações. Coberturas vacinais – HPV Quadrivalente - Sexo feminino de 11 a 14 anos por idade e dose - Total Brasil – 2014 [Internet]. Brasília (DF): Ministério da Saúde; 2014 [cited 2020 Mar 12]. Available from: http://pni.datasus.gov.br/consulta_hpv_14_C01.php
• 7 Teixeira JC, Vianna MS, Vale DB. et al. School-based HPV vaccination: the challenges in a Brazilian initiative. Rev Bras Ginecol Obstet 2021; 43 (12) 923-931 DOI: 10.1055/s-0041-1740279.
• 8 Kreimer AR, Struyf F, Del Rosario-Raymundo MR. et al; Costa Rica Vaccine Trial Study Group Authors, PATRICIA Study Group Authors, HPV PATRICIA Principal Investigators/Co-Principal Investigator Collaborators, GSK Vaccines Clinical Study Support Group. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials. Lancet Oncol 2015; 16 (07) 775-786 DOI: 10.1016/S1470-2045(15)00047-9.
• 9 Vale DB, Silva MT, Discacciati MG, Polegatto I, Teixeira JC, Zeferino LC. Is the HPV-test more cost-effective than cytology in cervical cancer screening? An economic analysis from a middle-income country. PLoS One 2021; 16 (05) e0251688 DOI: 10.1371/journal.pone.0251688.
• 10 Teixeira JC, Vale DB, Campos CS, Bragança JF, Discacciati MG, Zeferino LC. Organization of cervical cancer screening with DNA−HPV testing impact on early−stage cancer detection: a population−based demonstration study in a Brazilian city. Lancet Reg Health Am 2022; 5: 100084 DOI: 10.1016/j.lana.2021.100084.